RxDoctor Payments Data

Narbeh Tovmassian, MD

Internal Medicine · Glendale, CANPI 1750643508

Payments from drug & device makers

$3,504in general payments, 2019–2025

Across 66 payments — averaging $53.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$1K
  • Abbott$717
  • Boston Scientific$644
  • Abiomed$286
  • Organogenesis Inc.$174
  • Medtronic$132
  • plus $475 from 11 others

What the payments were for

  • Food & beverage$3,504100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,504 in reported general payments places this provider in the 85th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$541,257
Medicare patients
1,338
Services billed
6,221

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide141$159,167
EliquisApixaban300$101,258
AustedoDeutetrabenazine29$100,930
JardianceEmpagliflozin139$98,525
JanuviaSitagliptin Phosphate137$72,005
OzempicSemaglutide51$55,623
XareltoRivaroxaban40$20,074
RybelsusSemaglutide17$18,680
VascepaIcosapent Ethyl48$18,651
EntrestoSacubitril/Valsartan36$17,747
Synjardy XrEmpagliflozin/Metformin Hcl25$16,972
LinzessLinaclotide28$15,749
FarxigaDapagliflozin Propanediol20$14,621
RocklatanNetarsudil Mesylat/Latanoprost25$9,278
ErtapenemErtapenem Sodium15$7,708

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$108$159,167141 claims
PfizerEliquis$27$101,258300 claims
Novo NordiskOzempic, Rybelsus$23$74,30368 claims
Johnson & JohnsonXarelto$1,076$20,07440 claims
AstraZenecaFarxiga$20$14,62120 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Glendale

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →